 Home > Active Ingredient News > Immunology News > Antibody drug conjugate ILUMYA (tildrakizumab-asmn) treatment of moderate-severe plaqueized psoriasis: good long-term safety effectiveness

Antibody drug conjugate ILUMYA (tildrakizumab-asmn) treatment of moderate-severe plaqueized psoriasis: good long-term safety effectiveness

 Last Update: 2020-06-16
 Source: Internet
 Author: User

Tags

2 4 dithiapentane

1 year treasury

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

The pharmaceutical company Sun today announced that it will present the long-term use and cost-benefit analysis of ILUMYATM (tildrakizumab-asmn, targeting IL-23) for the treatment of moderate to severe plaqueps at the 2020 American Society of Dermatology (AAD) virtual meetingA long-term analysis of reSURFACE 1 and 2 extended studies found that ILUMYA provided consistent and improved results for patients with moderate to severe plaque psoriasis who received up to four years of treatment without finding new safety risksIn addition, the safety of ILUMYA was confirmed in a five-year analysis that showed a lower incidence of malignant tumors from the fourth to the fifth yearMost malignancies are a single event, with a similar incidence to the general population in the United StatesAn after-the-fact analysis of 335 patients with moderate to severe plaque psoriasis found that patients who reached PASI 50 or higher after 6 months of iLUMYA treatment continued to improve and their response rate increased for up to three yearsThose who reached PASI-90 at the 28th week were improved rapidly as early as week 4

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

High Purity 99% BPN14770 Zatolmilast 1606974-33-7 In Stock Fast Ship to USA

CAS No.: 1606974-33-7

Pharm Grade

$1-1.1/UNIT FOB

High quality Thymosin α1 Pure CAS 62304-98-7 Thymosin Alpha 1 Thymalfasin

CAS No.: 62304-98-7

Pharmacy Grade

$12-15/UNIT FOB

Top quantity Imiquimod CAS NO 99011-02-6 White crystalline powder 99% API

CAS No.: 99011-02-6

Pharmacy Grade

$1800-1850/KG FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.